AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1816218 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysis
Number of subjects: 30
Study 1816218 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 30
Study 6356145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-beam irradiation
Number of subjects: 0
Study 6356145 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrons-only therapy
Number of subjects: 0
Study 6356145 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 6356145 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron or mixed-beam therapy
Number of subjects: 0
Study 29125915 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice taken before and after exercise
Number of subjects: 0
Study 29125915 — intervention group
Group type: COMPARATOR
Intervention: Control (no beetroot juice)
Number of subjects: 0
Study 26946121 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthLinks intervention
Number of subjects: 3302
Study 26946121 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthLinks plus wellness committees
Number of subjects: 3302
Study 26946121 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 3302
Study 25552615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme (12-week duration, regular follow-up visits to a specialised physiotherapist)
Number of subjects: 120
Study 25552615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 25552615 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Number of subjects: 120
Study 22731794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (higher frequency of follow-up)
Number of subjects: 155
Study 22731794 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group (lower frequency of follow-up)
Number of subjects: 155
Study 19962986 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier-onset puberty (serum testosterone levels >= 2.5 ng/mL at 15 years old, n = 87)
Number of subjects: 100
Study 19962986 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine allele carrier at the SRD5A2 V89L polymorphism
Number of subjects: 100
Study 18396081 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection with EMG assistance
Number of subjects: 23
Study 18396081 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injection without EMG assistance
Number of subjects: 23
Study 17121034 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) group with basic therapy and syndrome-differentiation dependent TCM treatment
Number of subjects: 397
Study 17121034 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) group treated with non-steroidal anti-inflammatory drugs and slow-acting antirheumatic drug
Number of subjects: 397
Study 13679479 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 1860
Study 10693638 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 30
Study 10693638 — intervention group
Group type: COMPARATOR
Intervention: MMF or AZA
Number of subjects: 30
Study 9349927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1.625 mg/day via pMDI
Number of subjects: 12
Study 9349927 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 1.60 mg/day via pMDI with integrated spacer
Number of subjects: 12
Study 9349927 — intervention group
Group type: COMPARATOR
Intervention: Placebo pMDI
Number of subjects: 12
Study 8394847 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4‐9 fragment ebiratide (60, 300, and 600 micrograms)
Number of subjects: 8
Study 8394847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3031976 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC-LE
Number of subjects: 45
Study 3031976 — intervention group
Group type: COMPARATOR
Intervention: VAC
Number of subjects: 45
Study 3031976 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC-LE (CNS positive patients)
Number of subjects: 45
Study 31128916 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS + NGAL
Number of subjects: 0
Study 31128916 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL-RNAi + LPS + NGAL
Number of subjects: 0
Study 31128916 — intervention group
Group type: COMPARATOR
Intervention: NGAL-RNAi + LPS
Number of subjects: 0
Study 31128916 — intervention group
Group type: COMPARATOR
Intervention: LPS
Number of subjects: 0
Study 26766637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% povidone iodine solution for at least 3 minutes
Number of subjects: 184
Study 26766637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal disinfectant (group A)
Number of subjects: 184
Study 26766637 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group B)
Number of subjects: 184
Study 25219351 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg BID for 3 days followed by topiramate 100 mg BID from days 4 to 10
Number of subjects: 0
Study 25219351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg QD for 8 days followed by topiramate 96 mg BID from days 9 to 22
Number of subjects: 0
Study 25219351 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 96 mg BID alone for 11 days followed by pioglitazone 30 mg QD and topiramate 96 mg BID from days 12 to 22
Number of subjects: 0
Study 22366878 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (80% of maximum) twice weekly for 10 weeks
Number of subjects: 18
Study 22366878 — intervention group
Group type: COMPARATOR
Intervention: Usual daily activities (Control group)
Number of subjects: 18
Study 19966592 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning‐Trained Group (MTG, 7:00‐9:00 hr)
Number of subjects: 16
Study 19966592 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening‐Trained Group (ETG, 17:00‐19:00 hr)
Number of subjects: 16
Study 18019884 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (structured and supervised walking program meeting three times per week for 1 hour)
Number of subjects: 164
Study 18019884 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (supervised yoga program meeting twice per week for 90 minutes)
Number of subjects: 164
Study 18019884 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 164
Study 15841103 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement during leuprolide acetate treatment
Number of subjects: 10
Study 15841103 — intervention group
Group type: COMPARATOR
Intervention: Induced hypogonadal condition (leuprolide plus placebo)
Number of subjects: 10
Study 11864781 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins A, C, and E
Number of subjects: 30
Study 11864781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10495461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap resampling method for bias correction in group sequential designs
Number of subjects: 0
Study 7743791 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal values of cardiac index (CI) 2.5 < or = CI < or = 3.5 L min‐1 m‐2
Number of subjects: 98
Study 7743791 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal values of cardiac index (CI > or = 4.5 L min‐1 m‐2)
Number of subjects: 98
Study 7743791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed venous oxygen saturation (SvO2) > or = 70% or (Sat a‐‐Sat v) < or = 20%
Number of subjects: 98
Study 7743791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Swan‐Ganz catheter with scheduled samples of mixed venous O2 saturation
Number of subjects: 98
Study 7743791 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical catheter with continuous SvO2 evaluation
Number of subjects: 98
Study 2035820 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 20
Study 2035820 — intervention group
Group type: COMPARATOR
Intervention: Etomidate-midazolam-fentanyl
Number of subjects: 20
Study 6119875 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, Atenolol
Number of subjects: 861
Study 6119875 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol, Disopyramide phosphate
Number of subjects: 861
Study 6119875 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide phosphate
Number of subjects: 861
Study 31423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 50 IU/kg per week for 50 weeks
Number of subjects: 56
Study 31423921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epoetin beta)
Number of subjects: 56
Study 31423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 56
Study 27886020 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CES
Number of subjects: 50
Study 27886020 — intervention group
Group type: COMPARATOR
Intervention: Sham CES
Number of subjects: 50
Study 25248845 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous muscles (triceps muscles of the left and right limbs)
Number of subjects: 0
Study 25248845 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-homologous muscles (biceps left limb and triceps right limb)
Number of subjects: 0
Study 24211698 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body resistance exercise (TOTRX)
Number of subjects: 49
Study 24211698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extensor exercise (LEXT)
Number of subjects: 49
Study 24211698 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 49
Study 22312038 — intervention group
Group type: EXPERIMENTAL
Intervention: Triventricular (TriV) pacing
Number of subjects: 43
Study 19998456 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expression of CD24 in HCT116 cells
Number of subjects: 10
Study 19998456 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of CD24 in HT29 cells
Number of subjects: 10
Study 19998456 — intervention group
Group type: COMPARATOR
Intervention: Control (normal tissue)
Number of subjects: 10
Study 17561792 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 57
Study 17561792 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin (Control)
Number of subjects: 57
Study 15708175 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (80 mg of caffeine)
Number of subjects: 16
Study 15708175 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 16
Study 11998992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once-daily
Number of subjects: 31
Study 11998992 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 microg four-times daily
Number of subjects: 31
Study 10551290 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of dexamethasone sodium phosphate
Number of subjects: 19
Study 10551290 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of triamcinolone acetonide
Number of subjects: 19
Study 8703660 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 300 mg
Number of subjects: 20
Study 8703660 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 600 mg
Number of subjects: 20
Study 8703660 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 1200 mg
Number of subjects: 20
Study 8703660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8703660 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 20
Study 6809960 — intervention group
Group type: EXPERIMENTAL
Intervention: bacillus Calmette-Guerin
Number of subjects: 49
Study 6809960 — intervention group
Group type: COMPARATOR
Intervention: thio-tepa
Number of subjects: 49
Study 28064148 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 249
Study 28064148 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss + Aerobic Training (WL + AT)
Number of subjects: 249
Study 28064148 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss + Resistance Training (WL + RT)
Number of subjects: 249
Study 26394065 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaplasma strains genetically related to A. phagocytophilum
Number of subjects: 563
Study 26394065 — intervention group
Group type: EXPERIMENTAL
Intervention: A. ovis prevalence in adults (≥2 years)
Number of subjects: 563
Study 26394065 — intervention group
Group type: EXPERIMENTAL
Intervention: A. ovis prevalence in ewes vs rams
Number of subjects: 563
Study 26394065 — intervention group
Group type: EXPERIMENTAL
Intervention: A. ovis infection rate in local breed goats
Number of subjects: 563
Study 26394065 — intervention group
Group type: EXPERIMENTAL
Intervention: A. ovis infection rate in tick-infested goats
Number of subjects: 563
Study 24297687 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 24297687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 21953849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of median nerve deformation during finger motions
Number of subjects: 58
Study 19445434 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE intervention program
Number of subjects: 616
Study 19445434 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention (control group)
Number of subjects: 616
Study 21102210 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic continuous infusion device (pain pump) in addition to oral analgesics
Number of subjects: 54
Study 21102210 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics only
Number of subjects: 54
Study 21102210 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic continuous infusion device (pain pump)
Number of subjects: 54
Study 21102210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 15949082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked Merocel pack
Number of subjects: 57
Study 15949082 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked Merocel pack
Number of subjects: 57
Study 12139207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg tablet
Number of subjects: 12
Study 12139207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15321223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine-epinephrine
Number of subjects: 20
Study 15321223 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 20
Study 8187029 — intervention group
Group type: EXPERIMENTAL
Intervention: 443c81 (5 ml of a 4 mg/ml solution nebulized) four times daily for 7 days
Number of subjects: 40
Study 8187029 — intervention group
Group type: EXPERIMENTAL
Intervention: 443c81 (5 ml of a 4 mg/ml solution nebulized)
Number of subjects: 40
Study 8187029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3251339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous and oral doses of 50 mg of UDCA
Number of subjects: 10
Study 3251339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of 25, 100, and 300 mg of UDCA
Number of subjects: 10
Study 3251339 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA clearance in normal subjects
Number of subjects: 10
Study 3251339 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterohepatic circulation of UDCA
Number of subjects: 10
Study 12742480 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced tacrolimus (rTAC) with sirolimus (SRL)
Number of subjects: 64
Study 12742480 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus (sTAC) with sirolimus (SRL)
Number of subjects: 64
Study 31153789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group 1 (once a week)
Number of subjects: 222
Study 31153789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group 2 (twice a week)
Number of subjects: 222
Study 31153789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group 3 (three times a week)
Number of subjects: 222
Study 31153789 — intervention group
Group type: EXPERIMENTAL
Intervention: All Pilates groups (1, 2, and 3)
Number of subjects: 222
Study 31153789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 222
Study 27804067 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Activity-Rate (CA) infusion
Number of subjects: 22
Study 27804067 — intervention group
Group type: COMPARATOR
Intervention: Constant-Flow-Rate (CF) infusion
Number of subjects: 22
Study 27804067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 27281806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron and folic acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Number of subjects: 5011
Study 27281806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multiple micronutrient (MM) supplements (same amount of FA and iron plus other MMs)
Number of subjects: 5011
Study 27281806 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) supplements (2800 μg FA)
Number of subjects: 5011
Study 24933584 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation in the beginning of life
Number of subjects: 10
Study 22868283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube B (MINI One gastrostomy tube)
Number of subjects: 21
Study 22868283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube A (MIC-Key gastrostomy tube)
Number of subjects: 21
Study 22868283 — intervention group
Group type: COMPARATOR
Intervention: Both tube types
Number of subjects: 21
Study 20443499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid dosimetric constraints
Number of subjects: 0
Study 20443499 — intervention group
Group type: EXPERIMENTAL
Intervention: RT01-based dose-volume constraints
Number of subjects: 0
Study 20443499 — intervention group
Group type: EXPERIMENTAL
Intervention: CHHiP dose-volume constraints
Number of subjects: 0
Study 20443499 — intervention group
Group type: COMPARATOR
Intervention: Dose-volume constraints proposed by other researchers
Number of subjects: 0
Study 18560820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime powder solution (Group 1)
Number of subjects: 31
Study 18560820 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (Group 2)
Number of subjects: 31
Study 18560820 — intervention group
Group type: COMPARATOR
Intervention: Lactose as placebo (Group 3)
Number of subjects: 31
Study 15986401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven cancer care intervention, monthly meetings for 6 months with an oncology nurse, using an interactive computer program.
Number of subjects: 99
Study 15986401 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 99
Study 12566634 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Number of subjects: 109
Study 12566634 — intervention group
Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 109
Study 10475150 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 microg subcutaneous injections at 18:00 h and 23:00 h)
Number of subjects: 14
Study 10475150 — intervention group
Group type: COMPARATOR
Intervention: Saline (subcutaneous injections at 18:00 h and 23:00 h)
Number of subjects: 14
Study 10475150 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 microg)
Number of subjects: 14
Study 10475150 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study 8611872 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative enteral feeding through a nasojejunal tube
Number of subjects: 30
Study 8611872 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative intravenous fluids
Number of subjects: 30
Study 1931399 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg i.m.
Number of subjects: 10
Study 1931399 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 10
Study 6214264 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine
Number of subjects: 19
Study 6214264 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g cholestyramine
Number of subjects: 19
Study 6214264 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g cholestyramine
Number of subjects: 19
Study 6214264 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of cholestyramine
Number of subjects: 19
Study 31743169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg (D 1)
Number of subjects: 190
Study 31743169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (D 0.5)
Number of subjects: 190
Study 31743169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg (D 0.25)
Number of subjects: 190
Study 31743169 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 190
Study 31743169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 190
Study 30253746 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 20
Study 30253746 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - cycling
Number of subjects: 20
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aveeno lotion
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprobase cream
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublebase gel
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromol ointment
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Other non-study emollients
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diaries
Number of subjects: 197
Study 27852708 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer blinding
Number of subjects: 197
Study 24492633 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT‐Q‐7d (Dutch version)
Number of subjects: 453
Study 24492633 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT‐Q‐7d (English version)
Number of subjects: 453
Study 22162175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 51
Study 22162175 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus abciximab
Number of subjects: 51